NMDA受体NR2B特异性拮抗剂Ifenprodil对CCI大鼠神经病理性疼痛的预防作用

目的:观察预先给予ifenprodil是否可以预防坐骨神经慢性压榨性损伤(CCI)大鼠的神经病理性疼痛。方法:体重在180～200g的雄性SD大鼠随机分为4组:假手术 生理盐水组、假手术 ifenprodil组、CCI 生理盐水组及CCI ifenprodil组。建立外周神经慢性压榨性损伤(CCI)动物模型,假手术组大鼠同样分离坐骨神经,但不结扎神经。假手术 ifenprodil组及CCI ifenprodil组大鼠在术前30min及术后第1、2d连续三天腹腔内注射ifenprodil(10mg/kg);假手术 生理盐水组及CCI 生理盐水组大鼠则以同体积生理盐水代替ifenprodil进行腹腔内注射。使用vonFrey纤维测量大鼠手术侧机械痛阈。比较各组大鼠手术前后的机械痛阈。结果:CCI 生理盐水组大鼠的机械痛阈在术后第7d及14d均明显低于术前(P<0.05);其余各组大鼠的机械痛阈在术后较术前无显著性差异(P>0.05);CCI ifenprodil组大鼠术后7d及14d的机械痛阈显著高于CCI 生理盐水组(P<0.05)。结论:预先给予选择性作用于NR2B亚基的NMDA受体拮抗剂(ifen-prodil)可有效预防外周神经损伤所导致的神经病理性疼痛。因此NR2B的活化在神经病理性疼痛的形成过程中起重要作用。     

慢性坐骨神经缩窄损伤导致大鼠背根神经节内质网应激反应

目的:研究坐骨神经慢性缩窄(chronic constriction injury,CCI)引起大鼠背根神经节内质网应激反应。方法:56只SD雄性大鼠随机分为两组:假手术组(sham组)和手术组(CCI组)(n=28)。手术前、术后1天、4天、7天、14天、21天和28天测定动物机械痛敏和热痛敏,背根神经节GRP78葡萄糖调节蛋白78(glucose-regulated protein 78,GRP78,内质网应激反应的标志蛋白)的含量。结果:与假手术组相比,CCI组的机械痛阈和热痛阈在术后明显下降,背根神经节GRP78蛋白表达在第1天开始升高,第7天达到高峰。结论:坐骨神经慢性缩窄模型可以激活大鼠背根神经节GRP78蛋白表达和内质网应激反应,可能与神经病理性疼痛的形成有关。     

右美托咪定及舒芬太尼联合鞘内注射对CCI模型大鼠的镇痛效应

目的:研究右美托咪定及舒芬太尼联合鞘内注射对CCI模型大鼠的镇痛效应.方法:鞘内置管成功的雄性SD大鼠50只,随机分成5组:假手术组(Sham组);模型对照组(CCI组);右美托咪定组(Dex组);舒芬太尼组(Suf组);右美托咪定+舒芬太尼组(DS组).Dex组、Suf组、DS组分别于术后1～14d每天鞘内注射右美托咪定(dexmedetomidine,Dex)2 μg/(kg.d)、舒芬太尼(sufentanil,Suf)1 μg/d、Dex 1 μg/(kg.d)+Suf 0.5 μg/d;各组药物总容量均配成20μl,CCI组注射等体积0.9％生理盐水.每组分别在术前、术后l、3、7、14d给药30 min后,测定机械痛阈和热痛阈.于术后第7、14d痛阈值测定后,分批提取大鼠L4～6节段脊髓(n=5/组),应用免疫组化法检测脊髓背角Fos蛋白表达水平.结果:与Sham组相比,CCI组、Dex组、Suf组及DS组术后机械痛阈和热痛阈显著降低(P＜0.05),术后7 d c-fos蛋白表达上调(P＜0.05).与CCI模型组相比,Dex组、Suf组及DS组在术后3d、7d、14 d机械痛阈和热痛阈显著升高(P＜0.05),c-fos蛋白表达水平在术后7d差异显著(P＜0.05).与DS组相比,Dex组及Suf组在术后3d、7d、14 d机械痛阈及热痛阈显著降低(P＜0.05),c-fos蛋白在术后7d表达显著增加(P＜0.05).结论:鞘内联合应用右美托咪定及舒芬太尼治疗神经病理性疼痛具有显著的协调镇痛作用,能有效缓解CCI模型大鼠的机械痛敏及热痛敏.     

氯胺酮对神经病理性疼痛大鼠脊髓P2X_4受体mRNA表达的影响

目的:研究氯胺酮对神经病理性疼痛大鼠脊髓P2X_4受体mRNA表达的影响.方法:雄性SD大鼠45只,体重180～220g,随机分为假手术组(S组)、对照组(C组)和氯胺酮Ⅰ、Ⅱ、Ⅲ组(KⅠ、Ⅱ、Ⅲ组),每组9只.S组大鼠仅分离坐骨神经但不结扎,其余组建立坐骨神经慢性压迫性损伤(CCI)模型,K Ⅰ、Ⅱ、Ⅲ组分别于CCI后3d开始至取材点每天腹腔注射氯胺酮5mg/kg、10mg/kg、20mg/kg;S组和C组注射相同体积的生理盐水.各组大鼠分别于术前1d,术后3d、7d、14d、21d测定大鼠机械性痛觉过敏(MWT)和热痛觉过敏(TWL).各组均分别于CCI术后7d、14d、21d取3只大鼠,测定痛阈后处死,取L_(4～5)脊髓组织,用逆转录PCR(RT-PCR)方法测定P2X_4受体mRNA表达水平.结果:与术前及S组比较,C组、K Ⅰ、Ⅱ、Ⅲ组术后3d开始热痛阈及机械痛阈显著降低(P＜0.05).与C组比较,K Ⅰ、Ⅱ、Ⅲ组术后7d,14d,21d热痛阈及机械痛阈显著升高(P＜0.05).与S组比较,C组、K Ⅰ、Ⅱ、Ⅲ组大鼠脊髓P2X_4受体表达在术后7d、14d、21d均显著增加(P＜0.05);与C组大鼠比较,K Ⅰ、Ⅱ、Ⅲ组脊髓P2X_4受体表达明显减少(P＜0.05).结论:腹腔注射氯胺酮可抑制慢性神经痛大鼠痛觉过敏,该作用可能是通过作用于P2X_4受体介导的.     

鞘内注射地塞米松对神经病理性疼痛的影响

目的:通过大鼠鞘内注射免疫抑制剂地塞米松,探讨其对神经病理性疼痛的影响及机制,为疼痛的治疗提供新的途径。方法:将36只SD大鼠随机分成假手术 盐水治疗组、坐骨神经慢性压迫损伤(CCI) 盐水治疗组、CCI 地塞米松治疗组,每组12只。采用改良CCI法制作神经病理性疼痛模型,假手术 盐水治疗组只暴露坐骨神经而不予结扎,CCI 地塞米松治疗组大鼠于术后即刻、2、4、6、8、10、12天通过鞘内放置的PE-10导管予地塞米松0.5 mg(约0.1 mL),假手术 盐水治疗组和CCI 盐水治疗组大鼠在相同时间点予等容量的0.9%氯化钠。于术后1、3、7、14天测定大鼠的机械痛阈值,并于术后14天将大鼠处死,应用免疫组化技术测定其脊髓星形胶质细胞神经胶质原纤维酸性蛋白(GFAP)及肿瘤坏死因子-α(TNFα-)的表达。结果:坐骨神经结扎后痛阈下降,术后1、3、7、14天,CCI 盐水治疗组和CCI 地塞米松组的痛阈与假手术 盐水治疗组比较差异有统计学意义(P<0.01);CCI 地塞米松组痛阈与CCI 盐水治疗组比较有统计学意义(P<0.05)。免疫组化测定:假手术 盐水治疗组GFAP染色及TNFα-染色以阴性居多,CCI 盐水治疗组和CCI 地塞米松组GFAP染色为强阳性;CCI 盐水治疗组TNFα-染色弱阳性居多,CCI 地塞米松组TNFα-染色以强阳性居多,两者比较差异有统计学意义(P<0.05)。结论:地塞米松对神经病理性疼痛有明显的治疗作用。     

电针镇痛与神经病理性疼痛大鼠脊髓大麻素2受体表达

目的:观察电针对慢性坐骨神经缩窄性损伤(CCI)模型大鼠的镇痛效果及脊髓背角、背根神经节大麻素2受体(CB2)表达,探讨电针镇痛可能的机制.方法:健康SD雄性大鼠共40只,随机分为CCI假手术组(n=10);CCI对照组(n=10);CCI假电针组(n=10);CCI电针组(n=10).所有大鼠均在术前、术后第9、11、13、15、16d进行机械性痛阈测定;各组大鼠于术后第16d,采用Western blot法测定脊髓背角、背根神经节CB2受体蛋白表达.结果:CCI对照组、CCI假电针组和CCI电针组大鼠在治疗前机械性痛阈较术前明显下降,与同一时间段CCI假手术组大鼠比较差异有统计学意义(P＜0.05).治疗后6d,CCI电针组机械性痛阈较治疗前有一定改善(P＜0.05);CCI电针组与CCI假电针组和CCI对照组比较脊髓背角、背根神经节CB2的表达有下降的趋势,但差异无统计学意义(P＞0.05).结论:本研究观察到电针治疗能够在一定程度上改善CCI模型大鼠的机械性痛阈,起到一定的镇痛效果,但是本研究结果未能提示其镇痛机制有脊髓背角、背根神经节CB2的参与.     

神经病理性疼痛大鼠脊髓IL-33蛋白表达的变化

目的:观察外周神经慢性压榨性损伤(chronic constrictive injury,CCI)大鼠脊髓白介素-33(interleukin-33,IL-33)表达的变化规律。方法:雄性Wistar大鼠60只,分为手术组和假手术组,每组30只,于CCI前1天、CCI后第1、4、7、14、21天各时间点测定机械痛阈及热痛阈后立即处死大鼠,每个时间点5只,取L4~6脊髓,采用Western blot方法测定IL-33的蛋白表达变化。结果:手术组大鼠术侧机械痛阈及热痛阈明显降低,脊髓IL-33水平表达增加,明显高于对侧和假手术组术侧;IL-33蛋白水平于CCI后第1天开始增加,第7天达到高峰(P<0.01),于CCI后第21天仍维持于较高水平(P<0.05)。结论:CCI致大鼠脊髓IL-33活化,参与神经病理性疼痛的调控过程。     

腹腔联合注射氯胺酮及可乐定对CCI模型大鼠的镇痛效应

目的:研究氯胺酮及可乐定对慢性神经病理性疼痛模型大鼠的镇痛作用,并探讨其可能机制.方法:雄性SD大鼠60只,体重180～220g,随机分为假手术组(S组)、生理盐水组(NS组)、可乐定组(CL组)、氯胺酮组(K组)及氯胺酮+可乐定(KC组)组,每组12只.采用坐骨神经慢性压迫法(CCI)制备大鼠神经病理性痛模型,S组仅暴露坐骨神经,不结扎.K组、CL组和KC组于术后3～14d每天分别腹腔注射氯胺酮(10mg/kg)、可乐定(1m/kg)、氯胺酮(5mg/kg)+可乐定(0.5m/kg),S组和NS组腹腔注射等容量生理盐水.各组分别于术前、术后3、7、14d测定机械痛阈和热痛阈值,术后3、7、14d测定痛阈值后每组随机取4只大鼠断头处死,取腰段脊髓(L4～L6)背根神经节(DRG),采用逆转录PCR法(RT-PCR)检测GAP-43mRNA的表达水平.结果:与S组比较,NS组、K组、CL组和KC组术后机械痛阈和热痛阈降低,NS组、K组和CL组DRG中GAP-43mRNA表达上调,KC组仅在术后3d DRG中GAP-43mRNA表达上调(P＜0.05);与C组比较,K组、CL组和KC组术后机械痛阈和热痛阈升高,DRG中GAP-43mRNA表达下调(P＜0.05);与K组和CL组比较,KC组术后7、14d时机械痛阈和热痛阈升高,DRG中GAP-43mRNA表达下调(P＜0.05).结论:氯胺酮与一定剂量的可乐定联合应用能抑制神经病理性疼痛大鼠机械性触诱发痛和热痛觉过敏的形成,减少大鼠脊髓DRG中GAP-43mRNA的表达,具有显著的协同镇痛作用.     

2-氨基-5-磷酰基戊酸酯对大鼠坐骨神经慢性压迫性损伤的机械痛敏和热痛敏的影响

目的:建立大鼠坐骨神经慢性压迫性损伤(CCI)动物模型,腹腔注射N-甲基-D-天冬氨酸(NMDA)受体竞争性拮抗剂2-氨基-5-磷酰基戊酸酯(AP5)后观察腹腔用药对大鼠坐骨神经慢性压迫性损伤(CCI)动物模型机械痛敏和热痛敏的影响.方法:48只成年Wistar大鼠,雌雄不拘,随机分成3组,即Ⅰ组,假手术组(Sham),8只大鼠;Ⅱ组,CCI组,8只大鼠;Ⅲ组,治疗组,32只大鼠再分为4个亚组,Ⅲa组(CCI+NS),mb组[CCI+AP50.1mg/(kg·d)]、Ⅷc组(CCI+AP50.2 mg/kg)、Ⅲd组(CCI+AP50.5 mg/kg),每个亚组8只大鼠.48只大鼠分别于术前(0 d)及术后1、3、5、7、14、21 d测量每组大鼠的机械性缩足反射阈值(MWT)和热缩腿潜伏期(TWL).结果:CCI组从术后第3天开始直到本实验观察的术后第21天,MWT和TWL均明显降低,与假手术组Sham相比具有显著性(P＜0.01);CCI加生理盐水组大鼠与CCI组大鼠的MWT和TWL相比无明显改变(P＞0.05);腹腔注射AP5各个剂量的CCI组在术后5～21 d的MWT和TWL明显增加,与给药前和生理盐水组相比具有显著性(P＜0.01).结论:腹腔注射AP5有明显减轻大鼠CCI模型的机械性痛敏和热痛敏的作用.     

鞘内注射米贝地尔抑制慢性坐骨神经结扎大鼠机械痛敏和热痛敏

目的:观察脊髓水平T型钙通道阻滞剂米贝地尔(mibefradil)对坐骨神经慢性松结扎(CCI)大鼠机械和热痛阈的影响,探讨脊髓T型钙通道在伤害性信息传递中的作用.方法雄性SD大鼠48只,随机分为6组(n=8):假手术组(Sham),CCI组,CCI 生理盐水组,CCI 米贝地尔50 μg、100 μg、200 μg组.CCI组和Sham组在术前、术后1 d、3 d、5 d、7 d、14 d、21d测定大鼠机械缩腿阈值(MWT)和热缩腿潜伏期(TWL);其余各组大鼠在手术前5天先进行鞘内置管,在术前测定基础MWT和TWL,CCI手术后5 d鞘内注射不同剂量的米贝地尔,测定给药前、给药后0.5 h、1 h、2 h、4h、8 h大鼠MWL和TWL.结果:CCI组从术后3 d开始直到本实验观察的术后21 d,MWT和TWL均明显降低,与Sham组相比具有显著性意义(P＜0.01);CCI加生理盐水组大鼠在各个时间点上与给药前相比MWT和TWL无明显改变(P＞0.05);CCI加米贝地尔各个剂量组大鼠在给药后MWT和TWL均逐渐增加,具有剂量依赖性,并随时间的延长又逐渐恢复到给药前水平,CCI 米贝地尔200μg在给药后1 h时作用最明显,与给药前和盐水组相比P＜0.01,并一直持续到给药后4h.结论:鞘内注射米贝地尔能明显减轻慢性坐骨神经松结扎大鼠机械痛敏和热痛敏,提示T型钙通道在脊髓水平参与疼痛信息传递.     

Local application of the endocannabinoid hydrolysis inhibitor URB597 reduces nociception in spontaneous and chemically induced models of osteoarthritis

The present study examined whether enhancement of endogenous cannabinoid levels by administration of the fatty acid amide hydrolase inhibitor URB597 could modulate joint nociception in 2 rodent models of osteoarthritis (OA). OA-like changes were induced in male Wistar rats by intra-articular injection of monoiodoacetate, while Dunkin-Hartley guinea pigs (age 9-12 months) develop OA naturally and were used as a model of spontaneous OA. Joint nociception was measured by recording electrophysiologically from knee joint primary afferents in response to noxious hyper-rotation of the joint before and after close intra-arterial injection of URB597 (0.03 mg; 0.1 mL bolus); the CB₁ receptor antagonist AM251 (1 mg/kg intraperitoneally) or the CB₂ receptor antagonist AM630 (1 mg/kg intraperitoneally). The effect of systemic URB597 administration (5 mg/kg) on joint pain perception in the monoiodoacetate model was determined by hindlimb incapacitance. Peripheral injection of URB597 caused afferent firing rate to be significantly reduced by up to 56% in the rat OA model and by up to 69% in the guinea pig OA model. Systemic co-administration of AM251, but not AM630, abolished the antinociceptive effect of URB597 in both models. URB597 had no effect in saline-injected control rat joints or in nonarthritic guinea pigs. Systemic URB597 administration significantly reduced hindlimb incapacitance in monoiodoacetate joints and co-administration of the CB₁ antagonist abolished this effect. Local injection of URB597 into OA knee joints reduces mechanonociception and pain, and this response is mediated by CB₁ receptors. Targeting endocannabinoid-metabolizing enzymes in the peripheral nervous system could offer novel therapeutic approaches for the treatment of OA pain.     

The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice

Fatty acid amide hydrolase (FAAH) is an intracellular serine hydrolase that catalyzes the cleavage of bioactive fatty acid ethanolamides, such as the endogenous cannabinoid agonist anandamide. Genetic deletion of the faah gene in mice elevates brain anandamide levels and amplifies the antinociceptive effects of this compound. Likewise, pharmacological blockade of FAAH activity reduces nocifensive behavior in animal models of acute and inflammatory pain. In the present study, we investigated the effects of the selective FAAH inhibitor URB597 (KDS-4103, cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) in the mouse chronic constriction injury (CCI) model of neuropathic pain. Oral administration of URB597 (1-50 mg/kg, once daily) for 4 days produced a dose-dependent reduction in nocifensive responses to thermal and mechanical stimuli, which was prevented by a single i.p. administration of the cannabinoid CB(1) receptor antagonist rimonabant (1 mg/kg). The antihyperalgesic effects of URB597 were accompanied by a reduction in plasma extravasation induced by CCI, which was prevented by rimonabant (1 mg/kg i.p.) and attenuated by the CB(2) antagonist SR144528 (1 mg/kg i.p.). Oral dosing with URB597 achieved significant, albeit transient, drug levels in plasma, inhibited brain FAAH activity, and elevated spinal cord anandamide content. The results provide new evidence for a role of the endocannabinoid system in pain modulation and reinforce the proposed role of FAAH as a target for analgesic drug development.     

Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation

Fatty acid amide hydrolase (FAAH) is an intracellular serine enzyme that catalyzes the hydrolysis of bioactive fatty acid ethanolamides such as anandamide and oleoylethanolamide (OEA). Genetic deletion of the faah gene in mice elevates brain anandamide levels and amplifies the effects of this endogenous cannabinoid agonist. Here, we show that systemic administration of the selective FAAH inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester; 0.3 mg/kg i.p.) increases anandamide levels in the brain of rats and wild-type mice but has no such effect in FAAH-null mutants. Moreover, URB597 enhances the hypothermic actions of anandamide (5 mg/kg i.p.) in wild-type mice but not in FAAH-null mice. In contrast, the FAAH inhibitor does not affect anandamide or OEA levels in the rat duodenum at doses that completely inhibit FAAH activity. In addition, URB597 does not alter the hypophagic response elicited by OEA (5 and 10 mg/kg i.p.), which is mediated by activation of peroxisome proliferator-activated receptor type-alpha. Finally, exogenously administered OEA (5 mg/kg i.p.) was eliminated at comparable rates in wild-type and FAAH-/- mice. Our results indicate that URB597 increases brain anandamide levels and magnifies anandamide responses by inhibiting intracellular FAAH activity. The results also suggest that an enzyme distinct from FAAH catalyzes OEA hydrolysis in the duodenum, where this lipid substance acts as a local satiety factor.     

Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats

Emerging evidence suggests that the rewarding, abuse-related effects of nicotine are modulated by the endocannabinoid system of the brain. For example, pharmacological blockade or genetic deletion of cannabinoid CB(1) receptors can reduce or eliminate many abuse-related behavioral and neurochemical effects of nicotine. Furthermore, doses of Delta(9)-tetrahydrocannabinol and nicotine that are ineffective when given alone can induce conditioned place preference when given together. These previous studies have used systemically administered CB(1) receptor agonists and antagonists and gene deletion techniques, which affect cannabinoid CB(1) receptors throughout the brain. A more functionally selective way to alter endocannabinoid activity is to inhibit fatty acid amide hydrolase (FAAH), thereby magnifying and prolonging the effects of the endocannabinoid anandamide only when and where it is synthesized and released on demand. Here, we combined behavioral and neurochemical approaches to evaluate whether the FAAH inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester) could alter the abuse-related effects of nicotine in rats. We found that URB597, at a dose (0.3 mg/kg) that had no behavioral effects by itself, prevented development of nicotine-induced conditioned place preference (CPP) and acquisition of nicotine self-administration. URB597 also reduced nicotine-induced reinstatement in both CPP and self-administration models of relapse. Furthermore, in vivo microdialysis showed that URB597 reduced nicotine-induced dopamine elevations in the nucleus accumbens shell, the terminal area of the brain's mesolimbic reward system. These findings suggest that FAAH inhibition can counteract the addictive properties of nicotine and that FAAH may serve as a new target for development of medications for treatment of tobacco dependence.     

北京市医院消毒剂使用情况调查

目的了解北京市各级医疗机构消毒剂使用情况。方法采用现场抽样方法对54所医院进行了调查。结果在所调查的医院中,有72.22%的医院同时索取消毒剂生产企业卫生许可证和卫生许可批件(含备案凭证)。有46.30%的医院建立了消毒剂日常配制记录;38.89%的医院建立了消毒剂生物监测记录;61.11%的医院建立了消毒剂化学监测记录。医院的消毒剂储存条件整体较好。结论北京市各级医疗机构使用消毒剂的管理不够完善,卫生监督机构需要进一步加强监督管理。     

甲型肝炎病毒感染性灭活与抗原性破坏的比较

经比较，在３００μＷ／ｃｍ２紫外线照射下，ＨＡＶ颗粒感染性灭活速度远快于抗原性的破坏。经１％过氧化氢作用的ＨＡＶ颗粒，其感染性灭活速度与抗原性破坏速度基本呈平行关系，作用６０分钟，感染性消失，抗原性亦被破坏。     

医疗用品消毒管理情况调查

目的了解医院特殊医疗器材消毒管理情况,以便改进和加强管理。方法采用现场考察和填写调查表方法对临床特殊医疗器材的消毒技术和管理情况进行了专题调研。结果医院市场采购的一次性医疗用品主要采用环氧乙烷灭菌法,少数采用电离辐射灭菌法;使用后需要进行消毒处理者主要使用含氯消毒剂和戊二醛消毒剂处理。全院使用的一次性注射器、输液器、导尿管、胃管、吸痰管等物品抽样检测全部合格。各科室常用医疗器械使用后消毒处理多数采用含氯消毒剂浸泡处理;复用前灭菌多数采用戊二醛浸泡法,少数采用压力蒸汽灭菌法,仍有用低效消毒剂处理的情况。结论该医院一次性医疗用品灭菌质量能够得到保证,使用后处理和常用医疗器械消毒与灭菌处理存在不规范情况,需要改进提高。     

手术室空气消毒管理现状调查

目的了解江西省不同级别医疗机构手术室空气消毒方法的应用与管理情况。方法对11个地级市所有有手术室的医院进行了调查。结果江西省各级医疗机构手术室空气消毒主要使用消毒液熏蒸法、消毒液喷雾法、紫外线照射法、循环风紫外线空气消毒机、静电吸附式空气消毒机等方法。有46.49%的医疗机构的手术室采用其中1种消毒方法;有42.26%的医疗机构手术室使用2种消毒方法;有11.33%的医疗机构手术室同时拥有3种消毒方法。仍有77.08%的医疗机构手术室使用了紫外线照射消毒法,使用循环风紫外线空气消毒机的占37.50%,使用静电吸附式空气消毒机的只占11.46%。有81.64%的医疗机构接受疾病预防控制机构的消毒效果检测,有82.43%的医疗机构可进行自我检测。结论江西省各级医疗机构手术室都进行空气消毒,所使用的消毒方法不尽相同,以使用紫外线消毒法的居多,多数手术室能接受监督管理。